TheraRadar
← Back
Data updated: Jul 17, 2026

YIMMUGO

Biotech
Pharmaceuticals

YIMMUGO is a biotechnology company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

YIMMUGO's Key Drugs

YIMMUGO's core commercial portfolio centers on YIMMUGO — its most strategically important drugs approved in the last 15 years.

YIMMUGO
Approved 2024

YIMMUGO's Recent FDA Approvals

New NDA/BLA approvals for YIMMUGO over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

YIMMUGO's Therapeutic Areas

Disease areas where YIMMUGO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

YIMMUGO Pipeline Snapshot

Active clinical trials for YIMMUGO across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • YIMMUGO leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling